Analyst firms · Morgan Stanley · TAK

Morgan Stanley TAK price target and rating history

Takeda Pharmaceutical Company Limited (TAK) · Health Care

Morgan Stanley rates Takeda Pharmaceutical Company Limited (TAK) Overweight, as of its latest action on Jan 13, 2026. It has published 3 rating actions on TAK since October 2021, including 1 upgrade and 1 downgrade.

Current rating
Overweight
Price target
Not stated
Median target, all firms
Too few
Actions on TAK
3

Every Morgan Stanley rating on TAK

How other firms rate TAK

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BernsteinOutperformApr 8, 2026
Morgan StanleyOverweightJan 13, 2026

Questions about Morgan Stanley and TAK

What is Morgan Stanley's rating on TAK?
Morgan Stanley rates TAK Overweight, a bullish rating, as of Jan 13, 2026.
When did Morgan Stanley last change its view on TAK?
On Jan 13, 2026, Morgan Stanley resumes coverage at Overweight.

All Morgan Stanley ratingsTAK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.